AI English summary of an SEC filing — figures as filed
3M MMM3M said it completed the separation of its health care business on April 1, 2024, distributing 80.1% of the outstanding shares of Solventum Corporation to 3M stockholders on a pro rata basis under the 3M. Stockholders of record as of the close of business on 3M received 1 share of Solventum common stock for every 4 shares of 3M common stock.
Key points
AI summary3M said it completed the separation of its health care business on April 1, 2024, distributing 80.1% of the outstanding shares of Solventum Corporation to 3M stockholders on a pro rata basis under the 3M. Stockholders of record as of the close of business on 3M received 1 share of Solventum common stock for every 4 shares of 3M common stock.
The company said it will continue to hold a 19.9% stake in Solventum and measure it at fair value. About 34 million shares were valued at $2.4 billion based on the closing price of $69.10 on April 1, 2024, and the company estimated a gain of $1.6 billion on the investment immediately after the separation.
The company said Solventum had $8.4 billion in aggregate principal amount of debt upon completion of the separation. It said the cash payments to 3M from the Solventum financings, after fees, discounts and expenses, were about $7.7 billion, and Solventum retained $0.6 billion of cash and cash equivalents.
The company reported pro forma net sales of $24.8 billion for 2023 ($32.7 billion as previously reported) and a pro forma net loss from continuing operations attributable to 3M of $6.5 billion ($7.0 billion as previously reported). The income statement assumes the separation occurred on January 1, 2023 and reclassifies Solventum as discontinued operations for all periods presented.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Solventum Separation Completed: 80.1% Distributed
3M said it completed the separation of its health care business on April 1, 2024, distributing 80.1% of the outstanding shares of Solventum Corporation to 3M stockholders on a pro rata basis under the 3M. Stockholders of record as of the close of business on 3M received 1 share of Solventum common stock for every 4 shares of 3M common stock.
Source · Based on the filing body and exhibits
Remaining 19.9% Stake and Estimated Gain of $1.6 billion
The company said it will continue to hold a 19.9% stake in Solventum and measure it at fair value. About 34 million shares were valued at $2.4 billion based on the closing price of $69.10 on April 1, 2024, and the company estimated a gain of $1.6 billion on the investment immediately after the separation.
Source · Based on the filing body and exhibits
About $7.7 billion in Cash Received Tied to Solventum Borrowings
The company said Solventum had $8.4 billion in aggregate principal amount of debt upon completion of the separation. It said the cash payments to 3M from the Solventum financings, after fees, discounts and expenses, were about $7.7 billion, and Solventum retained $0.6 billion of cash and cash equivalents.
Source · Based on the filing body and exhibits
2023 Pro Forma Sales and Continuing Operations Loss
The company reported pro forma net sales of $24.8 billion for 2023 ($32.7 billion as previously reported) and a pro forma net loss from continuing operations attributable to 3M of $6.5 billion ($7.0 billion as previously reported). The income statement assumes the separation occurred on January 1, 2023 and reclassifies Solventum as discontinued operations for all periods presented.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…